Table 1.

Association between GP96 overexpression and clinicopathological parameters

	Total patients		GP96 over-expression
			No		Yes
	No.	%	No.	%	No.	%	P
Gender							0.518*
Male	77	97.5	23	30	54	70
Female	2	2.5	1	50	1	50
Age (years)							0.573
≤ 48	44	51	11	27.5	29	72.5
> 48	39	49	13	33	26	67
Smoking							0.573*
No	14	18	4	29	10	71
Yes	65	82	20	31	45	69
Drinking							0.237
No	19	24	4	21	15	79
Yes	60	76	20	33	40	67
Betel-quid chewing							0.427*
No	14	18	5	36	9	64
Yes	65	82	19	29	46	71
Stage							0.349*
I-II	13	16.5	5	38.5	8	61.5
III-IV	66	83.5	19	29	47	71
T stage							0.390
T1-2	36	46	12	33	24	67
T3-4	43	54	12	28	31	72
Nodal stage							0.020
N0-1	44	56	18	41	26	59
N2	35	44	6	17	29	83
Nodal ECS							0.183
No	45	57	16	33	29	67
Yes	34	43	8	23.5	26	76.5
Differentiation							0.654
Well	24	30	9	37.5	15	62.5
Moderate	47	60	13	28	34	72
Poor	8	10	2	25	6	75
Depth (millimeters)							0.045
≤10	30	38	13	43	17	57
> 10	49	62	11	22	38	78
Skin invasion							0.641*
No	72	91	22	31	50	69
Yes	7	9	2	29	5	71
Bone invasion							0.402
No	56	71	18	32	38	68
Yes	23	29	6	26	17	74
Perineural invasion							0.424
No	53	67	15	28	38	72
Yes	24	30	8	33	16	67
Missing	2	3
Blood Vessel invasion
No	72	91	22	31	50	69	0.528*
Yes	5	6	1	20	4	80
Missing	2	3
Lymphatic vessel invasion							0.069*
No	65	82	22	34	43	66
Yes	12	15	1	8	11	92
Missing	2	3
Margin status (millimeters)							0.605*
≥ 5	66	83.5	20	30	46	70
< 5	13	16.5	4	31	9	69

* Fisher's exact test

Abbreviations: ECS = extracapsular spreading